SynthesisBrain and behavior2026
Vitamin D Supplementation and its Effect on Relapse Frequency and MRI Activity in Adults With Multiple Sclerosis: A Systematic Review.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLiterature evidence links vitamin D supplementation to clinical outcomes in multiple sclerosis (MS), yet no systematic review has focused specifically on relapse rate and MRI activity. Thus, this systematic review aimed to evaluate the effect of vitamin D supplementation on relapse rate and magnetic resonance imaging (MRI) disease activity in adults with clinically diagnosed MS.
methodsThis systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed, Cochrane, EBSCO, and Web of Science were searched for studies discussing vitamin D supplementation in adults with diagnosed MS. Annualized relapse rate (ARR) and changes in MRI activity were the primary outcome measures. Non-randomized studies and randomized controlled trials were assessed for their risk of bias using the Cochrane ROBINS-I and RoB-2 tools, respectively.
resultsOf 304 records identified, 127 duplicates were removed and 177 were screened, with 11 primary studies (14 reports) included after full-text review. Across studies, vitamin D supplementation did not suggest a reduced ARR with most randomized trials reporting no significant difference between groups. One trial using alfacalcidol provides evidence for a reduction in relapse risk, but this was not replicated. MRI outcomes were more variable, with several studies showing reductions in inflammatory lesion activity, while others found no significant effect. Overall, results were inconsistent, and due to heterogeneity in study design and reporting, findings were synthesized narratively without meta-analysis.
conclusionVitamin D supplementation does not consistently reduce relapse rates in adults with MS, although some studies report improvement in MRI activity. The overall certainty of evidence is limited by variation in study design, patient population, cohort size, and risk of bias. Current data does not support vitamin D as a disease-modifying therapy beyond correction of deficiency; further, larger, standardized trials are needed to clarify its clinical role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.